Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Biogen

Medicare weighs premium cut after limiting Alzheimer's drug

Medicare says it’s considering a cut in enrollee premiums, after officials stuck with an earlier decision to sharply limit coverage for a pricey new Alzheimer’s drug projected to drive up program costs

The Independent UK

Medicare to pay for Biogen’s Alzheimer’s drug only when used in clinical trials

The U.S. Medicare program finalized a plan to only pay for Biogen Inc.’s Alzheimer’s therapy when it’s used in approved clinical trials, while offering a road map to cover drugs that do show clinical benefit in the disease.

Tribune News Service

Biogen's ALS Drug Won't Move Forward After Trial Failures

Biogen will stop developing a drug to treat a severe neurodegenerative disease, as it did not show sufficient benefit when tested in trials.

The Street

From analysis to the latest developments in health,
read the most diverse news in one place.

Ionis-Biogen Partnered Amyotrophic Lateral Sclerosis Trial Disappoints

Biogen Inc (NASDAQ: BIIB) and Ionis Pharmaceuticals Inc (NASDAQ: IONS) have

Benzinga

3 Wide-Moat Stocks That Look Cheap: Biogen, Medtronic, and Bristol-Myers Squibb

: Major stock indices appear heading for weekly gains with the Fed’s first interest rate hike digested easily by investors. However, the market is expected to remain under pressure in the near term. So, because wide-moat companies generally do well in these market conditions, we think cheap wide-moat stocks Bristol-Myers…

StockNews.com

Biogen lays out awaited Alzheimer’s drug data in obscure journal

Biogen Inc. on Wednesday published the full efficacy results from two late-stage studies of its Alzheimer’s disease drug Aduhelm in a lesser-known medical journal, nine months after U.S. regulators cleared the treatment.

Tribune News Service

Biogen Shares Aduhelm Data In Alzheimer's Disease At 128 Weeks

Biogen Inc (NASDAQ:BIIB) has announced new data from the long-term extension phase of the Phase 3 trials of Aduhelm (aducanumab-avwa) in Alzheimer's disease. The data exhibited that after nearly two and a half years of treatment (128 weeks) with Aduhelm, patients continued to experience significant reductions in two key Alzheimer's disease pathologies, amyloid-beta…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Biogen Says It Solved The Alzheimer's Puzzle, But Investors May Need More Evidence

Patients who received Biogen's Alzheimer's drug for over two years showed slower cognitive decline — leading Biogen stock to tick higher.

Investors Business Daily

Biogen, Eisai Amend Their Alzheimer's Drug Marketing Pact

Eisai Co Ltd (OTC:ESALY) is giving up its right to share in profits from Aduhelm (aducanumab-avwa), which was developed in partnership with Biogen Inc (NASDAQ:BIIB). Biogen and Eisai have amended their agreement to give Biogen full authority to make regulatory and sales decisions regarding Aduhelm. From 2023, Eisai will receive royalties starting at 2% of…

Benzinga

The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Biogen Posts New Updates Across its Spinraza SMA Research Program

Biogen Inc (NASDAQ: BIIB) announced new data and updates from its Spinraza (nusinersen) and spinal muscular atrophy (SMA) research program, including the ASCEND, RESPOND and NURTURE studies.

Benzinga

Why This Analyst Sees Roughly 20% Upside In This Large-Cap Biopharma

Biogen Inc (NASDAQ: BIIB) shares are now trading notably off their all-time high of $468.55 hit on June 7, achieved on the back of Aduhel

Benzinga

Expert Ratings For Biogen

Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following analyst ratings:

Benzinga

Biogen Snags Upgrade On Alzheimer's Hopes, And Then Announces Layoffs

Biogen stock popped Thursday after an analyst suggested it could reap $8 billion in sales of its Alzheimer's treatments.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Tribune News Service

Inside the tactical tug of war over the controversial Alzheimer’s drug

The drug industry, patient advocates and congressional Republicans have all attacked federal officials’ decision to decline routine Medicare coverage for a controversial Alzheimer’s drug. They’ve gone as far as to accuse them of tacit racism, ageism and discrimination against the disabled — and hinted at a lawsuit — over the…

Investors Business Daily

Why A Biogen-Sage Drug Flopped — And Could Still Be Approved

Investors questioned the durability of Sage's depression treatment on Wednesday, and Sage stock collapsed to a nearly two-year low.

Tribune News Service

Patients’ groups, progressives square off over Medicare Alzheimer’s decision

WASHINGTON — Advocates on both sides of a debate over dramatically restricting Medicare’s coverage of an expensive and controversial Alzheimer’s treatment are waging competing campaigns to influence a final decision in April.

Roll Call

Patients' groups, progressives square off over Medicare Alzheimer's decision - Roll Call

Competing campaigns look to influence the debate over dramatically restricting coverage of a controversial treatment drug Aduhelm.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Biogen-Xbrane Enter License Agreement For Cimzia Referenced Biosimilar, Xcimzane

Biogen Inc (NASDAQ: BIIB) and Xbrane Biopharma AB have

Benzinga

The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Biogen's Aduhelm Approval, Marketing Comes Under FTC, SEC Probes

The Federal Trade Commission (FTC) and the Securities and Exchange Commission (SEC) have launched two separate investigations into Biogen Inc (NASDAQ: BIIB) and its Alzheimer's med, Aduhelm (aducanumab).

Benzinga

What 24 Analyst Ratings Have To Say About Biogen

Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following analyst ratings:

Benzinga

Analyst Ratings For Biogen

Analysts have provided the following ratings for Biogen (NASDAQ:BIIB) within the last quarter:

Benzinga

Biogen's Return On Capital Employed Insights

Benzinga Pro data, Biogen (NASDAQ:BIIB) reported Q4 sales of $2.73 billion. Earnings fell to a loss of $20.50 million, resulting in a 106.44% decrease from last quarter. In Q3, Biogen earned $318.10 million, and total sales reached $2.78 billion.

Benzinga

Biogen's Alzheimer's Drug Clocks Q4 Sales Of Just $1M, FY22 Earnings Guidance Below Consensus

Biogen Inc (NASDAQ: BIIB) posted Q4 sales of 2.73 billion, beating the consensus of $

1 … 9 10 11 12

People

Brian Abrahams

61 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Securities and Exchange Commission

Federal Trade Commission

Read news from The Economist, FT, and more,
with one subscription

Places

United States

250,307 stories

43 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.